FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia

Naval Daver, Paolo Strati, Elias Jabbour, Tapan Kadia, Raja Luthra, Sa Wang, Keyur Patel, Farhad Ravandi, Jorge Cortes, Xiao Qin Dong, Hagop Kantarjian, Guillermo Garcia-Manero

Research output: Contribution to journalArticle

Abstract

FMS-like tyrosine kinase III (FLT3) mutations occur in one-third of acute myeloid leukemia (AML) patients and predict poor outcome. The incidence and impact of FLT3 in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is unknown. We conducted a retrospective review to identify WHO MDS and CMML patients with FLT3 mutations at diagnosis. A total of 2,119 patients with MDS and 466 patients with CMML were evaluated at MD Anderson between 1997 and 2010. Of these, FLT3 mutation analysis was performed on 1,232 (58%) MDS and 302 (65%) CMML patients. FLT3 mutations were identified in 12 (0.95%) MDS patients: 9 (75%) had FLT3-ITD mutation and 3 had FLT3-tyrosine kinase domain (TKD) mutation. MDS patients with FLT3 mutations were younger (P = 0.02) and presented as RAEB (P = 0.03) more frequently. Median overall survival (OS) for FLT3-mutated MDS patients was 19.0 months versus 16.4 months for FLT3-nonmutated MDS patients (P = 0.08). FLT3 mutations were identified in 13 (4.3%) CMML patients: 8 had FLT3-ITD mutation and 5 had FLT3-TKD mutation. There were no significant differences in demographic and disease characteristics among CMML patients with and without FLT3 mutations. Median OS for FLT3-mutated CMML patients was 10.8 months versus 21.3 months for FLT3-nonmutated CMML patients (P = 0.12). FLT3 occurs in MDS and CMML at a lower frequency than AML and does not predict poor outcome.

Original languageEnglish (US)
Pages (from-to)56-59
Number of pages4
JournalAmerican Journal of Hematology
Volume88
Issue number1
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Leukemia, Myelomonocytic, Chronic
Myelodysplastic Syndromes
Mutation
Protein-Tyrosine Kinases
Acute Myeloid Leukemia
Refractory Anemia with Excess of Blasts
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Daver, N., Strati, P., Jabbour, E., Kadia, T., Luthra, R., Wang, S., ... Garcia-Manero, G. (2013). FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. American Journal of Hematology, 88(1), 56-59. https://doi.org/10.1002/ajh.23345

FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. / Daver, Naval; Strati, Paolo; Jabbour, Elias; Kadia, Tapan; Luthra, Raja; Wang, Sa; Patel, Keyur; Ravandi, Farhad; Cortes, Jorge; Qin Dong, Xiao; Kantarjian, Hagop; Garcia-Manero, Guillermo.

In: American Journal of Hematology, Vol. 88, No. 1, 01.01.2013, p. 56-59.

Research output: Contribution to journalArticle

Daver, N, Strati, P, Jabbour, E, Kadia, T, Luthra, R, Wang, S, Patel, K, Ravandi, F, Cortes, J, Qin Dong, X, Kantarjian, H & Garcia-Manero, G 2013, 'FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia', American Journal of Hematology, vol. 88, no. 1, pp. 56-59. https://doi.org/10.1002/ajh.23345
Daver, Naval ; Strati, Paolo ; Jabbour, Elias ; Kadia, Tapan ; Luthra, Raja ; Wang, Sa ; Patel, Keyur ; Ravandi, Farhad ; Cortes, Jorge ; Qin Dong, Xiao ; Kantarjian, Hagop ; Garcia-Manero, Guillermo. / FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. In: American Journal of Hematology. 2013 ; Vol. 88, No. 1. pp. 56-59.
@article{ceab138fbbc046b9bc1d5a1ce504082a,
title = "FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia",
abstract = "FMS-like tyrosine kinase III (FLT3) mutations occur in one-third of acute myeloid leukemia (AML) patients and predict poor outcome. The incidence and impact of FLT3 in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is unknown. We conducted a retrospective review to identify WHO MDS and CMML patients with FLT3 mutations at diagnosis. A total of 2,119 patients with MDS and 466 patients with CMML were evaluated at MD Anderson between 1997 and 2010. Of these, FLT3 mutation analysis was performed on 1,232 (58{\%}) MDS and 302 (65{\%}) CMML patients. FLT3 mutations were identified in 12 (0.95{\%}) MDS patients: 9 (75{\%}) had FLT3-ITD mutation and 3 had FLT3-tyrosine kinase domain (TKD) mutation. MDS patients with FLT3 mutations were younger (P = 0.02) and presented as RAEB (P = 0.03) more frequently. Median overall survival (OS) for FLT3-mutated MDS patients was 19.0 months versus 16.4 months for FLT3-nonmutated MDS patients (P = 0.08). FLT3 mutations were identified in 13 (4.3{\%}) CMML patients: 8 had FLT3-ITD mutation and 5 had FLT3-TKD mutation. There were no significant differences in demographic and disease characteristics among CMML patients with and without FLT3 mutations. Median OS for FLT3-mutated CMML patients was 10.8 months versus 21.3 months for FLT3-nonmutated CMML patients (P = 0.12). FLT3 occurs in MDS and CMML at a lower frequency than AML and does not predict poor outcome.",
author = "Naval Daver and Paolo Strati and Elias Jabbour and Tapan Kadia and Raja Luthra and Sa Wang and Keyur Patel and Farhad Ravandi and Jorge Cortes and {Qin Dong}, Xiao and Hagop Kantarjian and Guillermo Garcia-Manero",
year = "2013",
month = "1",
day = "1",
doi = "10.1002/ajh.23345",
language = "English (US)",
volume = "88",
pages = "56--59",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia

AU - Daver, Naval

AU - Strati, Paolo

AU - Jabbour, Elias

AU - Kadia, Tapan

AU - Luthra, Raja

AU - Wang, Sa

AU - Patel, Keyur

AU - Ravandi, Farhad

AU - Cortes, Jorge

AU - Qin Dong, Xiao

AU - Kantarjian, Hagop

AU - Garcia-Manero, Guillermo

PY - 2013/1/1

Y1 - 2013/1/1

N2 - FMS-like tyrosine kinase III (FLT3) mutations occur in one-third of acute myeloid leukemia (AML) patients and predict poor outcome. The incidence and impact of FLT3 in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is unknown. We conducted a retrospective review to identify WHO MDS and CMML patients with FLT3 mutations at diagnosis. A total of 2,119 patients with MDS and 466 patients with CMML were evaluated at MD Anderson between 1997 and 2010. Of these, FLT3 mutation analysis was performed on 1,232 (58%) MDS and 302 (65%) CMML patients. FLT3 mutations were identified in 12 (0.95%) MDS patients: 9 (75%) had FLT3-ITD mutation and 3 had FLT3-tyrosine kinase domain (TKD) mutation. MDS patients with FLT3 mutations were younger (P = 0.02) and presented as RAEB (P = 0.03) more frequently. Median overall survival (OS) for FLT3-mutated MDS patients was 19.0 months versus 16.4 months for FLT3-nonmutated MDS patients (P = 0.08). FLT3 mutations were identified in 13 (4.3%) CMML patients: 8 had FLT3-ITD mutation and 5 had FLT3-TKD mutation. There were no significant differences in demographic and disease characteristics among CMML patients with and without FLT3 mutations. Median OS for FLT3-mutated CMML patients was 10.8 months versus 21.3 months for FLT3-nonmutated CMML patients (P = 0.12). FLT3 occurs in MDS and CMML at a lower frequency than AML and does not predict poor outcome.

AB - FMS-like tyrosine kinase III (FLT3) mutations occur in one-third of acute myeloid leukemia (AML) patients and predict poor outcome. The incidence and impact of FLT3 in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is unknown. We conducted a retrospective review to identify WHO MDS and CMML patients with FLT3 mutations at diagnosis. A total of 2,119 patients with MDS and 466 patients with CMML were evaluated at MD Anderson between 1997 and 2010. Of these, FLT3 mutation analysis was performed on 1,232 (58%) MDS and 302 (65%) CMML patients. FLT3 mutations were identified in 12 (0.95%) MDS patients: 9 (75%) had FLT3-ITD mutation and 3 had FLT3-tyrosine kinase domain (TKD) mutation. MDS patients with FLT3 mutations were younger (P = 0.02) and presented as RAEB (P = 0.03) more frequently. Median overall survival (OS) for FLT3-mutated MDS patients was 19.0 months versus 16.4 months for FLT3-nonmutated MDS patients (P = 0.08). FLT3 mutations were identified in 13 (4.3%) CMML patients: 8 had FLT3-ITD mutation and 5 had FLT3-TKD mutation. There were no significant differences in demographic and disease characteristics among CMML patients with and without FLT3 mutations. Median OS for FLT3-mutated CMML patients was 10.8 months versus 21.3 months for FLT3-nonmutated CMML patients (P = 0.12). FLT3 occurs in MDS and CMML at a lower frequency than AML and does not predict poor outcome.

UR - http://www.scopus.com/inward/record.url?scp=84871437507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871437507&partnerID=8YFLogxK

U2 - 10.1002/ajh.23345

DO - 10.1002/ajh.23345

M3 - Article

C2 - 23115106

AN - SCOPUS:84871437507

VL - 88

SP - 56

EP - 59

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -